Intersect ENT (XENT) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Trump threatens to bomb Oman over Iran stance
Intersect ENT Reports Fourth Quarter and Year 2015 Results
February 23, 2016 4:05 PM ESTFull Year Revenue Increased 60% Year Over Year; Gross Margin at 80%
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2015.
Fourth quarter revenue was $18.8 million, representing a 40% increase over the fourth quarter 2014. Full year 2015 revenue was $61.6 million, representing a 60% increase over full year 2014. Fourth quarter gross margin was 80% compared to 78%... MoreIntersect ENT Appoints David Lehman General Counsel
February 22, 2016 4:05 PM ESTMENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of David Lehman as general counsel. Mr. Lehman brings three decades of legal experience to Intersect ENT, most recently having served as general counsel and secretary for Thoratec Corporation (NASDAQ: THOR), a global leader in medical technology to address advanced-stage heart failure, where he saw the company through tremendous growth and eventual sale to St. Jude... More
